What Is ARA-290?
ARA-290 is a erythropoietin-derived peptide supplied by Peptegrity for research and educational purposes. This page provides a factual educational overview of ARA-290, including its classification, biological target, research background, terminology and published study context. It is not a product page and does not provide dosing instructions, treatment recommendations or personal-use guidance.
Type of compound
ARA-290 is an 11-amino acid synthetic peptide derived from the structure of erythropoietin (EPO). It is classified as an erythropoietin-derived peptide that mimics the tissue-protective properties of EPO without stimulating erythropoiesis.
Biological target and mechanism
The peptide functions as a specific agonist of the innate repair receptor (IRR), a heteroreceptor complex composed of the EPO receptor and the CD131 beta common receptor [5]. Research suggests that by activating this pathway, ARA-290 may modulate neuro-inflammatory processes and interact with the TRPV1 channel to investigate pain-related signaling mechanisms [3].
Research background
ARA-290 was developed to investigate the tissue-protective effects of erythropoietin signaling while avoiding the hematopoietic effects of full-length EPO. It has been primarily investigated in the context of nerve fiber health, immune system interaction, and endothelial cell function [2], [5].
Current research and development status
ARA-290 is currently an investigational research compound. It is not approved by the FDA, TGA, or any other regulatory body for clinical therapeutic use in humans.
Published research context
Published research has evaluated the compound's potential effects on small fiber neuropathy, particularly in subjects with sarcoidosis, measuring impacts on symptoms and corneal nerve fiber density [1], [2], [4]. Other studies have explored the biochemical integration between immune signaling and nociception [3], as well as the peptide's influence on the function of endothelial colony-forming cells [5].
Relevant terminology
The innate repair receptor (IRR) is a protein complex that, when activated, is associated with anti-inflammatory and tissue-protective outcomes. Erythropoiesis refers to the production of red blood cells, a process which the ARA-290 peptide is designed to avoid, distinguishing it from full-length erythropoietin.
Storage and handling terminology
Research peptides are typically supplied as lyophilized powders and should be stored in a controlled environment, such as a freezer at -20°C or -80°C. Once reconstituted, peptides are subject to degradation and should be handled according to specific laboratory protocols to maintain stability.
Testing and Certificate of Analysis (COA)
A Certificate of Analysis (COA) is a document provided by manufacturers to confirm the purity, identity, and potency of a research compound. Researchers should verify that a COA includes data from analytical techniques such as High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) to ensure quality standards.
Regulatory status
ARA-290 is restricted to laboratory research and development purposes only. It is not approved for sale as a medication, dietary supplement, or for any human use.
This page is for research and educational purposes only. It is not intended to provide medical advice, dosing instructions, or treatment recommendations, and does not represent any product as approved to diagnose, treat, cure or prevent any disease. Compounds described here may be investigational or unapproved medicines; regulatory status is summarised for information only.
Frequently asked questions
What is ARA-290?
ARA-290 is an 11-amino acid peptide derived from erythropoietin designed to study tissue-protective signaling through the innate repair receptor.
How does ARA-290 differ from erythropoietin?
Unlike full-length erythropoietin, ARA-290 is engineered to target tissue-protective pathways without stimulating red blood cell production.
What are the common research applications for ARA-290?
Current research involving ARA-290 focuses on its role in neuro-inflammation, endothelial cell function, and its potential impact on corneal nerve fiber density [1], [3], [5].
Is ARA-290 an approved drug?
No, ARA-290 is an investigational compound intended for laboratory research purposes and is not approved by regulatory agencies for therapeutic use.
References
- 1.ARA 290 for treatment of small fiber neuropathy in sarcoidosisPubMed
- 2.Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot studyPubMed
- 3.ARA 290 relieves pathophysiological pain by targeting TRPV1 channel: Integration between immune system and nociceptionPubMed
- 4.Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With SarcoidosisClinicalTrials.gov
- 5.ARA290, a Specific Agonist of Erythropoietin/CD131 Heteroreceptor, Improves the Function of Endothelial Colony-Forming CellsPubMed
